Attached files
| file | filename |
|---|---|
| EX-23.2 - EXHIBIT 23.2 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex23-2.htm |
| EX-32.1 - EXHIBIT 32.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex32-1.htm |
| EX-31.1 - EXHIBIT 31.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex31-1.htm |
| EX-21.1 - EXHIBIT 21.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex21-1.htm |
| EX-31.2 - EXHIBIT 31.2 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex31-2.htm |
| EX-16.1 - EXHIBIT 16.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex16-1.htm |
| 10-K - FORM 10-K - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-205929) of Cynapsus Therapeutics Inc. (the “Company”), of our report dated March 8, 2016, relating to the Company’s consolidated statements of financial position as at December 31, 2015 and 2014, and the Company’s consolidated statements of loss and comprehensive loss, changes in shareholders’ equity and cash flows for the years ended December 31, 2015 and 2014, which appear in this Annual Report on Form 10-K.
| /s/ Ernst & Young LLP | |
| Chartered Professional Accountants | |
| Licensed Public Accountants |
Toronto, Canada
March 9, 2016